25.05
price up icon6.23%   1.47
after-market アフターアワーズ: 25.05
loading
前日終値:
$23.58
開ける:
$23.6
24時間の取引高:
1.16M
Relative Volume:
1.25
時価総額:
$2.07B
収益:
$352.57M
当期純損益:
$-143.01M
株価収益率:
-5.5543
EPS:
-4.51
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+4.16%
1か月 パフォーマンス:
+10.16%
6か月 パフォーマンス:
+0.68%
1年 パフォーマンス:
-15.00%
1日の値動き範囲:
Value
$23.18
$25.43
1週間の範囲:
Value
$23.18
$25.87
52週間の値動き範囲:
Value
$20.84
$49.50

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
名前
Beam Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
857-327-8775
Name
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
職員
374
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
BEAM's Discussions on Twitter

BEAM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BEAM 25.05 2.07B 352.57M -143.01M -153.40M -4.51
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-01-29 アップグレード JP Morgan Neutral → Overweight
2023-12-15 ダウングレード BofA Securities Buy → Neutral
2023-12-08 ダウングレード Jefferies Buy → Hold
2023-10-20 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-10-20 ダウングレード Leerink Partners Outperform → Market Perform
2023-03-21 開始されました Bernstein Mkt Perform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2022-12-20 アップグレード BMO Capital Markets Market Perform → Outperform
2022-12-13 開始されました Citigroup Buy
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-04-28 開始されました Credit Suisse Neutral
2022-01-05 開始されました Guggenheim Buy
2021-10-19 開始されました SVB Leerink Outperform
2021-09-24 再開されました Stifel Buy
2021-09-10 開始されました BofA Securities Buy
2021-05-11 開始されました Redburn Buy
2021-05-04 開始されました RBC Capital Mkts Sector Perform
2021-03-01 ダウングレード Barclays Overweight → Equal Weight
2021-02-16 開始されました Wells Fargo Overweight
2021-01-29 ダウングレード JP Morgan Overweight → Neutral
2021-01-06 開始されました Stifel Hold
2020-08-05 開始されました William Blair Outperform
2020-03-02 開始されました Barclays Overweight
2020-03-02 開始されました JP Morgan Overweight
2020-03-02 開始されました Jefferies Buy
2020-03-02 開始されました Wedbush Outperform
すべてを表示

Beam Therapeutics Inc (BEAM) 最新ニュース

pulisher
Nov 21, 2024

Where are the Opportunities in (BEAM) - Stock Traders Daily

Nov 21, 2024
pulisher
Nov 21, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by Quest Partners LLC - MarketBeat

Nov 21, 2024
pulisher
Nov 19, 2024

Prime Editing and CRISPR Market Trends and Growth Opportunities - openPR

Nov 19, 2024
pulisher
Nov 16, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Short Interest Up 10.3% in October - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Beam Therapeutics management to meet virtually with Cantor Fitzgerald - Nasdaq

Nov 15, 2024
pulisher
Nov 15, 2024

Sumitomo Mitsui Trust Group Inc. Boosts Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Beam Therapeutics' SWOT analysis: base editing pioneer's stock faces market hurdles - Investing.com Australia

Nov 14, 2024
pulisher
Nov 13, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Sold by Baillie Gifford & Co. - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Bolsters Position in Beam Therapeutics Inc with Recent A - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Beam Therapeutics CEO to Present at Jefferies Healthcare Conference in London | BEAM Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Research Analysts Issue Forecasts for BEAM FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™

Nov 11, 2024
pulisher
Nov 10, 2024

Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 09, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 51,110 Shares - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Beam Therapeutics president sells $1.35 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 08, 2024

Insider Sale: President Giuseppe Ciaramella Sells Shares of Beam Therapeutics Inc (BEAM) - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Beam Therapeutics president sells $1.35 million in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

ARK Investment Management LLC Has $160.01 Million Stock Holdings in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimate for Beam Therapeutics Lowered by Analyst - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by Leerink Partnrs - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics (NASDAQ:BEAM) Given "Buy" Rating at HC Wainwright - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics Inc. (NASDAQ:BEAM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 07, 2024
pulisher
Nov 07, 2024

Wedbush Expects Reduced Earnings for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

William Blair Cuts Earnings Estimates for Beam Therapeutics - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Beam Therapeutics upgraded to Outperform from Market Perform at Leerink - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink Partners Upgrades Beam Therapeutics (BEAM) - MSN

Nov 07, 2024
pulisher
Nov 06, 2024

Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades despite fatality in gene editing trial - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Beam stock rebounds as Leerink upgrades (BEAM:NASDAQ) - Seeking Alpha

Nov 06, 2024
pulisher
Nov 06, 2024

Breaking Down Beam Therapeutics: 5 Analysts Share Their Views - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics (NASDAQ:BEAM) Raised to "Outperform" at Leerink Partners - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: P - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Beam points to positive data with key base editing asset - pharmaphorum

Nov 06, 2024
pulisher
Nov 06, 2024

Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Reports Steady Progress in Q3 2024 - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Patient Dies in Beam Trial of SCD Candidate; Company Cites Conditioning - Genetic Engineering & Biotechnology News

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 05, 2024
pulisher
Nov 05, 2024

Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - AOL

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 05, 2024

SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Beam’s early base editing clinical data overshadowed by patient death - The Business Journals

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics to Present Data Across Hematology - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down After Earnings Miss - MarketBeat

Nov 05, 2024

Beam Therapeutics Inc (BEAM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Beam Therapeutics Inc (BEAM) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Ciaramella Giuseppe
President
Oct 14 '24
Option Exercise
2.00
41,754
83,594
211,370
Ciaramella Giuseppe
President
Oct 14 '24
Sale
26.27
51,110
1,342,752
160,260
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
大文字化:     |  ボリューム (24 時間):